Sanofi (MIL:1SAN) Dividends Received

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

MIL:1SAN Sanofi SA MIL:1SAN
73 GF Score
Price €77.38
GF Value €107.55
Valuation Modestly Undervalued
! 2 Warning Signs
View Full Analysis

What is Sanofi Dividends Received?

Dividends Received only applicable to companies reporting Cash Flow from Operations in direct method.

MIL:1SAN
73GF Score
Sanofi SA MIL:1SAN
Dividends Received is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Sanofi (MIL:1SAN) Overvalued in 2026?

Based on GuruFocus' analysis, Sanofi stock appears to be undervalued. The current stock price of €77.38 is trading 28.1% below its estimated GF Value™ of €107.55. GuruFocus considers Sanofi to be Modestly Undervalued.

Key valuation signals for MIL:1SAN:

  • Dividends Received:
  • GF Value™: €107.55 vs. price of €77.38 (28.1% below fair value)
  • GF Score™: 73/100 with 2 warning signs

No single metric tells the full story. See the MIL:1SAN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Sanofi Business Description

Address 46, Avenue de la Great Army, Paris, FRA, 75017
Sanofi develops and markets drugs with a concentration in immunology, vaccines, and rare diseases. Although the company offers a diverse array of drugs, its highest revenue generator, Dupixent, accounts for over 30% of total sales. Profits for this immunology blockbuster drug are shared with Regeneron. About 45% of total revenue comes from the United States, 20% from Europe, and 6% from China.
73GF Score

Get the complete analysis for MIL:1SAN

Dividends Received is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€77.38
Price
€107.55
GF Value